Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Ertugliflozin is a type 2 sodium-glucose cotransporter inhibitor. It has similar actions to dapagliflozin and is used as monotherapy or with other antidiabetic therapy, including insulin, in the treatment of type 2 diabetes mellitus. Oral administration as a once-daily dosage or twice-daily dosage if combined with metformin.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, moderately high molecular weight and very high percentage of binding to plasma proteins) make passage into breast milk in clinically significant quantities very unlikely.
Pending further published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
See below the information of this related product: